Treatment outcomes and risk factors for severity and mortality in Clostridioides difficile infection: a single-center study in Thailand.|https://dx.doi.org/10.3855/jidc.20742
Fecal Microbiota-based therapies compared to Fecal Microbiota Transplantation for Preventing recurrent C. difficile Infection.|https://dx.doi.org/10.1016/j.cgh.2025.08.029
Bezlotoxumab for the prevention of recurrent Clostridioides difficile infection for patients with cancer.|https://dx.doi.org/10.20524/aog.2025.0994
Lipidomics, Microbiota, and Intestinal Clostridioides difficile Infection Outcome.|https://dx.doi.org/10.3390/ijms26178214
Assessment of chemical methods in the extraction of spore surface layers in Clostridioides difficile spores.|https://dx.doi.org/10.1128/msphere.00531-25
Activated PI3K Delta Syndrome: A Case Presentation and Literature Review.|https://dx.doi.org/10.7759/cureus.89884
Use of proximity ligation shotgun metagenomics to investigate the dynamics of plasmids and bacteriophages in the gut microbiome following fecal microbiota transplantation.|https://dx.doi.org/10.1080/19490976.2025.2559019
Fecal microbiota transplantation in recurrent Clostridioides difficile: Is greater methodological rigor and the analysis of other populations relevant?|https://dx.doi.org/10.1016/j.rgmxen.2025.09.022
Response to "Fecal microbiota transplantation in recurrent Clostridioides difficile: Is greater methodological rigor and the analysis of other populations relevant?".|https://dx.doi.org/10.1016/j.rgmxen.2025.09.023
